{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.2","value":"8590"}]}],"title":"AUClast"},{"categories":[{"measurements":[{"comment":"Although samples were collected for 26 participants, AUCtau could not be evaluated because extrapolated AUC was over 20% for all participants. AUCtau is derived from extrapolated AUC. However, when it is over 20% for all participants, AUCtau cannot be determined.","groupId":"OG000","spread":"NA","value":"NA"}]}],"title":"AUCtau"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.","id":"OG000","title":"Asciminib (All Asciminib)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full PK samples were collected at Week 2. Although samples were collected for 26 participants, AUCtau could not be evaluated because extrapolated AUC was over 20% for all participants.\n\nAUCtau is derived from extrapolated AUC. However, when it is over 20% for all participants, AUCtau cannot be determined.","reportingStatus":"POSTED","timeFrame":"Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)","title":"PK of Asciminib: AUCtau and AUClast","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}